Recent Updates
Recently added Catalysts
MANE Positive Sentiment

Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Sunday, October 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Veradermics, a biopharmaceutical company, will hold a conference call on October 19, 2026, to discuss the topline results from its Phase 3 clinical trial of VDPHL01 for mild-to-moderate pattern hair loss. This trial is part of a randomized, double-blind, placebo-controlled study. The event aims to provide insights into the efficacy and safety of the treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Veradermics is progressing with a Phase 3 clinical trial.
  • The company is focused on innovative therapeutics for hair loss.
  • The upcoming conference call indicates transparency and engagement with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~168 mo
Minimal dilution risk
Lead asset
VDPHL01
Phase 3 · Androgenetic Alopecia

Full Press Release Details

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Monday, October 19, 2026, at 8:00 am ET to review results from Part A of its randomized, double-blind, placebo-controlled registration-directed Phase 3 clinical trial (Study ‘304’) evaluating VDPHL01, a proprietary, extended-re

Frequently Asked Questions

What is the purpose of the conference call?

The conference call aims to discuss topline results from the Phase 3 clinical trial of VDPHL01.

When will the conference call take place?

The conference call is scheduled for October 19, 2026, at 8:00 am ET.

What type of study is the Phase 3 trial?

It is a randomized, double-blind, placebo-controlled registration-directed trial.

What condition is VDPHL01 targeting?

VDPHL01 is being evaluated for mild-to-moderate pattern hair loss.

ShareAdd on Google
Tags: MANE Veradermics VDPHL01 hair loss Phase 3 trial clinical trial
Last updated: Oct 18, 2026

Biotech snapshot

Cash runway
$820M liquidity · $5M/mo burn
~168 mo
Minimal dilution risk
Lead asset
VDPHL01Phase 3
Androgenetic Alopecia →